Project Grant R01NS138499
Award Date
9/1/24
Completion Date
7/31/29
Dollars Obligated
$1.1M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders provides $532,381 to Emory University to comprehensively investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key research objectives include: 1) determining the gain-of-function effects of KIF5ADE27...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,307,075 to The Leland Stanford Junior University (Stanford University) to support research aimed at defining novel mechanisms of neurodegenerative diseases and developing new therapeutic strategies. The key activities include: Using a combination of yeast and human genetics to...
The federal Project Grant award of $1,499,212.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders" supports the development of a novel oral, brain-penetrant therapeutic for amyotrophic lateral sclerosis (ALS) disease by Aquinnah Pharmaceuticals, Inc. The project aims to advance the manufacturing, IND-enabling studies, and a pre-IND meeting with the FDA for this...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $124,246 to the University of Massachusetts Medical School to develop advanced base and prime editing strategies to correct common SOD1 mutations that cause amyotrophic lateral sclerosis (ALS). The project aims to (1) create next-generation base editors with improved...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on understanding the role of the KIF5A gene in amyotrophic lateral sclerosis (ALS). The award of $121,554 to the University of California, San Diego (UCSD) will fund a research project with three key objectives: (1) investigating the impact of KIF5A ALS mutations...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,504,638 to the University of Utah to conduct research on PASK-regulated genes and proteins as therapeutic targets for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives are to: 1) identify phosphorylated peptides of the ATXN2...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the effects of re-expressing embryonic motor neuron selector transcription factors on amyotrophic lateral sclerosis (ALS) pathology. The $645,391 award, effective from December 1, 2024 to November 30, 2029, will be provided to The Trustees of Columbia...